You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Scientific Merit and Feasibility of Fructokinase Inhibiton for Obesity

    SBC: COLORADO RESEARCH PARTNERS LLC            Topic: NIDDK

    DESCRIPTION provided by applicant Intake of added sweeteners high fructose corn syrup and sucrose independently predicts the development of obesity metabolic syndrome and diabetes Despite recommendations by WHO and the AHA to reduce sugar intake to to percent of total energy intake the mean intake of added sugars remains percent of the diet and percent of the population ingest ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Development of iCrystal System for Rapid Crystallization of Biological Macromolecules

    SBC: JUXTOPIA LLC            Topic: 100

    DESCRIPTION provided by applicant Biological macromolecules are the machinery of life and understanding their function helps scientists to develop new drug treatments that target specific human diseases In this regard crystallization is routinely employed for the understanding of the molecular structures and the interactions of proteins with other biological and non biological materials Desp ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Smartphone Technology for Parents and Teens: Improving Vaccination Uptake

    SBC: KLEIN BUENDEL, INC.            Topic: NICHD

    DESCRIPTION provided by applicant Vaccinations for adolescents in the U S tetanus diphtheria and acellular pertussis Tdap meningococcal conjugate vaccine MCV Human Papillomavirus HPV vaccines Gardasil and Cervarex remain well below the Centers for Disease Control and Prevention CDC goals and especially so for the HPV vaccines These vaccine deficits are pronounced among minor ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Enhancing Care of the Aged and Dying in Prisons

    SBC: KLEIN BUENDEL, INC.            Topic: NIA

    DESCRIPTION provided by applicant The United States has the highest rate of incarceration in the world The demographics of the prison population are shifting In fact the number of sentenced state and federal prisoners age or older grew at times the rate of the overall prison population from The health status of aging inmates does not mirror the free world population In fac ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Therapeutics to Treat Candida albicans Biofilm Infections

    SBC: BIOSYNESIS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The yeast Candida albicans is a normal resident of the human digestive tract It is also the most common fungal pathogen of humans causing both mucosal and systemic infections particularly in immune compromised individuals The majority of new C albicans infections arise from the presence of persistent C albicans cells existing in a biofilm These biofilm b ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Effectiveness of VBP15, a dissociative steroidal analogue, on inflammation in a mouse model of arthritis

    SBC: ReveraGen BioPharma, Inc.            Topic: NIAMS

    DESCRIPTION provided by applicant Glucocorticoids GCandapos s such as prednisolone are used frequently to induce remission and treat rheumatoid arthritis RA Despite effectiveness many GC mediated detrimental side effects including osteoporosis and muscle atrophy limit long term chronic treatment of RA patients In addition juvenile arthritis patients suffer from th side effect of signi ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. ASTROCYTE ACTIVATION BY SMALL MOLECULE P2Y1 AGONISTS FOR TREATMENT OF TBI

    SBC: ASTROCYTE PHARMACEUTICALS INC.            Topic: 105

    DESCRIPTION provided by applicant Traumatic brain injuries TBI are an area of significant unmet need with no approved therapeutics and a national burden of $ billion annually Astrocyte Pharmaceuticals is developing a small molecule pharmaceutical agent that would be administered by intravenous injection by emergency responders or a medical professional within hours of injury to limit n ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Cloud quantitative imaging for whole-body tumor burden in neurofibromatoses

    SBC: IQ MEDICAL IMAGING LLC            Topic: 102

    DESCRIPTION provided by applicant The neurofibromatoses NFs including NF NF and schwannomatosis are a group of autosomal dominant neurogenetic disorders characterized by a predisposition in virtually of patients to develop multiple nerve sheath tumors The determination of tumor burden on magnetic resonance imaging MRI images is crucial for the management of NF patients which is ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction

    SBC: Molecular Express Inc            Topic: R42

    DESCRIPTION provided by applicant Heroin and related opioids are highly addictive drugs known for their analgesic properties Since the number of heroin users in the United States has skyrocketed reaching epidemic levels Abuse of prescription opioid pain relievers oxycodone Oxycotin and hydrocodone Vicodin which are known gateway drugs to heroin has also increased dramatically Beca ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Gene and Oligonucleotide Delivery System

    SBC: Molecular Express Inc            Topic: NCATS

    DESCRIPTION provided by applicant The knockdown of targeted genes by anti sense oligonucleotides ODNS and genetic medicines collectively G MEDS holds promise for a variety of therapies The delivery of effective quantities of ODNS to specific cells however has proved to be challenging We propose here a novel approach to ODN delivery that involves enveloped virus like particles EVLPs ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government